Fourth Quarter & Full Year 2022 Financial & Business Update
Three Strategic Pillars to Drive Impressive Growth - Capitalizing on
Seagen's Innovation Power
OPTIMIZE
full potential of
commercial portfolio
•
10 potentially registrational studies
ongoing with multiple upcoming
catalysts
Meaningful growth opportunity
through potential label expansions
•
Enhance commercial execution and
footprint
Seagen
•
=
PRIORITIZE
development of most
transformative assets
兆
INNOVATE
through next-generation
ADC technologies
Leverage synergies of vedotin ADCs
and PD-1s with 9+ combination trials
Prioritized portfolio focused on
differentiated assets, many with large
potential patient populations and global
rights
Optimize auristatin payload and
diversify beyond vedotin with novel
linkers and payloads
Supplement pipeline with
complementary assets through
strategic in-licensing
8View entire presentation